New research suggests that while screening for prostate cancer using a prostate-specific antigen (PSA) blood test can reduce mortality, the overall benefit is limited. The comprehensive study, which reviewed data from six trials involving almost 800,000 men, concluded that screening prevents approximately two deaths from prostate cancer for every 1,000 men tested. However, a significant concern highlighted is the potential for many men to undergo unnecessary treatment and face associated medical complications.
Prostate cancer is one of the most common cancers among men in the UK, with over 52,000 new cases diagnosed annually. The PSA test measures the level of PSA in the blood, a protein produced by the prostate gland. Elevated PSA levels can indicate prostate cancer, but can also be caused by other non-cancerous conditions, leading to false positives and subsequent biopsies or treatments that may not be necessary. This phenomenon, known as overdiagnosis and overtreatment, is a key concern for health professionals.
The findings underscore a long-standing debate within the medical community and among policymakers regarding the widespread implementation of prostate cancer screening programmes. While early detection can improve outcomes for aggressive cancers, the slow-growing nature of many prostate cancers means they may never cause harm during a man's lifetime. Treating these indolent cancers can lead to side effects such as incontinence and erectile dysfunction, significantly impacting quality of life without extending lifespan.
Currently, the NHS does not offer a national screening programme for prostate cancer. Instead, men over 50 can request a PSA test after discussing the pros and cons with their GP. This approach, known as 'informed choice', aims to ensure men understand the potential benefits and risks of testing before proceeding. The latest study provides further evidence to inform these crucial conversations between patients and healthcare providers, reinforcing the complexity of the decision.
For UK patients, these findings mean that while the PSA test can be a valuable tool, it is not without its drawbacks. Men considering the test should engage in a thorough discussion with their GP to weigh up the potential small benefit of preventing a prostate cancer death against the risk of overdiagnosis and subsequent unnecessary interventions. The NHS continues to emphasise personalised care and informed decision-making in this area.